help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on April 14, 2005, doi:10.1164/rccm.200409-1244OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200409-1244OCv1
172/1/99    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dobbin, C. J.
Right arrow Articles by Bye, P. T. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dobbin, C. J.
Right arrow Articles by Bye, P. T. P.
American Journal of Respiratory and Critical Care Medicine Vol 172. pp. 99-104, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200409-1244OC


Original Article

The Effect of Infective Exacerbations on Sleep and Neurobehavioral Function in Cystic Fibrosis

Catherine J. Dobbin, Delwyn Bartlett, Kerri Melehan, Ronald R. Grunstein and Peter T. P. Bye

Sleep Unit, Department of Respiratory Medicine, Royal Prince Alfred Hospital, and Sleep Research Group, Woolcock Institute for Medical Research, University of Sydney, Sydney, Australia

Correspondence and requests for reprints should be addressed to Catherine Dobbin, M.B.B.S. M.Med., Department of Respiratory Medicine, E 11 West, Royal Prince Alfred Hospital, Missenden Road, Sydney, NSW 2050, Australia. E-mail:cathd{at}mail.med.usyd.edu.au

Rationale: Adults with cystic fibrosis (CF) are susceptible to hypoxemia, hypercapnia, arousal from sleep, and neurobehavioral impairment. Objectives: We hypothesized that pulmonary exacerbations would adversely affect sleep and neurobehavioral performance. Methods: Patients with exacerbations (cases) had sleep studies and neurobehavioral testing before and after inpatient intravenous therapy. Adults with stable CF underwent the same testing procedures (control subjects). Measurements and Main Results: When clinically stable, cases and control subjects had similar lung function, intelligence, and body mass index. Among cases, treatment of an exacerbation improved lung function, quality of life, mood, sleepiness, and activation. Cases spent more time awake after sleep onset (p = 0.02), less time in REM sleep (p = 0.03), and were more hypoxemic than control subjects when unwell. The severity of hypoxemia correlated with lung function. On admission, cases had slower throughput than control subjects in the serial addition and subtraction task (cases, 16 ± 4, vs. control subjects, 17 ± 3; F[1, 36] = 5.15, p = 0.03) and a slower response time on the digit symbol substitution task (F[1, 36] = 11.91, p = 0.001), which persisted after treatment (F[1, 36] = 8.48, p = 0.006). Cases experienced significant improvements in sleep efficiency, amount of REM sleep, and hypoxia with treatment. Their performance in the serial addition and subtraction task, psychomotor vigilance task, and simulated driving task also improved with treatment. Sex modified the effect of an exacerbation on some aspects of performance. Conclusions: Exacerbations of lung disease in adults with CF adversely affect sleep and tests of neurobehavioral performance regardless of underlying disease severity. The implications for performance in daily life need further evaluation because patients often delay admission to hospital to fulfill study or work commitments.

Key Words: infective exacerbations • neurobehavioral function • sleep architecture • sleep-disordered breathing




This article has been cited by other articles:


Home page
Proc Am Thorac SocHome page
C. H. Goss and A. L. Quittner
Patient-reported Outcomes in Cystic Fibrosis
Proceedings of the ATS, August 1, 2007; 4(4): 378 - 386.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
S. C Bell and P. J Robinson
Exacerbations in cystic fibrosis: 2 {middle dot} Prevention
Thorax, August 1, 2007; 62(8): 723 - 732.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
K. R. Casey, K. O. Cantillo, and L. K. Brown
Sleep-Related Hypoventilation/Hypoxemic Syndromes
Chest, June 1, 2007; 131(6): 1936 - 1948.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
C. H Goss and J. L Burns
Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis
Thorax, April 1, 2007; 62(4): 360 - 367.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
J K Block, K L Vandemheen, E Tullis, D Fergusson, S Doucette, D Haase, Y Berthiaume, N Brown, P Wilcox, P Bye, et al.
Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria
Thorax, November 1, 2006; 61(11): 969 - 974.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
F. J. Accurso
Update in cystic fibrosis 2005.
Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 944 - 947.
[Full Text] [PDF]


Home page
Arch. Dis. Child.Home page
D S Urquhart, H Montgomery, and A Jaffe
Assessment of hypoxia in children with cystic fibrosis
Arch. Dis. Child., November 1, 2005; 90(11): 1138 - 1143.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society
  CCM abstracts